share_log

毕得医药(688073.SH):上半年净利润5183.91万元 同比下降38.15%

BiDe Pharmaceutical (688073.SH): The net income in the first half of the year was 51.8391 million yuan, a year-on-year decrease of 38.15%.

Gelonghui Finance ·  Aug 28, 2024 03:32

On August 28th, GeLong Hui announced its semi-annual report. The company achieved a revenue of 532.2073 million yuan during the reporting period, an increase of 1.83% year-on-year, with a net income attributable to the parent company of 51.8391 million yuan, a decrease of 38.15% year-on-year. Overseas revenue continued to grow rapidly, with the proportion of overseas revenue steadily increasing. During the reporting period, the company achieved revenue, with overseas revenue reaching 299.3019 million yuan, accounting for 56.24% of the total, compared to 265.6107 million yuan and 50.83% in the same period last year. The overseas revenue in the first half of 2024 increased by 12.68% year-on-year. The company's gross margin gradually stabilized, following market dynamics and adjusting pricing policies through strategic analysis, and it is expected that the gross margin will remain stable in the future.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment